Form D · Biotechnology
Orion Therapeutics, Inc.
Knoxville, TN · CIK 0001958173
Offering snapshot reported Sep 25, 2024 · SEC filing
- Reported sold
- $85K Offering amount: $250K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 10, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 25, 2024 | Initial | $85,000 | No comparison | 4 | SEC filing |
| Dec 14, 2022 | Initial | $60,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-524886
Source: Form D, filed Sep 25, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Kern Fisher | Director, Executive |
| Michael Mc Caman | Director, Executive |
| Deidra Mountain | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2641 Osprey Vista Way Lab 150 A
Knoxville, TN, 37920
Knoxville, TN, 37920